Opinion|Videos|November 9, 2023

Factors for Consideration When Employing UASs In Patients With Urinary Stones

Author(s)Michelle Semins, MD, Seth Bechis, MD

Drs Bechis and Semins discuss their approaches to employing ureteral access sheaths, reviewing assessing the ureter's caliber, dilation techniques, and the potential need for stenting post-sheath use, considering patient history and logistical factors like on-call availability.

Episodes in this series

EP. 1 Overview of the Incidence, Diagnosis, and Treatment of Urinary Stones

EP. 1 Overview of the Incidence, Diagnosis, and Treatment of Urinary Stones

EP. 2 The Evolving Role of Ureteroscopy in the Treatment of Urinary Stones

EP. 2 The Evolving Role of Ureteroscopy in the Treatment of Urinary Stones

EP. 3 Overview of Intrarenal Pressure (IRP)

EP. 3 Overview of Intrarenal Pressure (IRP)

EP. 4 Potential Complications Seen in Patients With Elevated IRP

EP. 4 Potential Complications Seen in Patients With Elevated IRP

EP. 5 Strategies for Reducing Risk of Elevated IRP

EP. 5 Strategies for Reducing Risk of Elevated IRP

EP. 6 Key Treatment and Outcome Data for Patients Undergoing Therapy with Assistance of Ureteral Access Sheaths (UASs)

EP. 6 Key Treatment and Outcome Data for Patients Undergoing Therapy with Assistance of Ureteral Access Sheaths (UASs)

EP. 7 Factors for Consideration When Employing UASs In Patients With Urinary Stones

EP. 7 Factors for Consideration When Employing UASs In Patients With Urinary Stones

EP. 8 Methods for Continuous IRP Monitoring in Patients With Urinary Stones

EP. 8 Methods for Continuous IRP Monitoring in Patients With Urinary Stones

EP. 9 Future Perspectives in the Treatment of Patients With Urinary Stones

EP. 9 Future Perspectives in the Treatment of Patients With Urinary Stones

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Residual stone volume outperforms stone-free rate as risk marker

ByBrett Johnson, MD

July 17th 2026

Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy

ByAmy E. Krambeck, MD

July 10th 2026

Study links unmet social needs with worse stone-specific quality of life

ByMichael John Mari Talagsa Uy, MD

July 6th 2026

From OR to office: How Break Wave changes urology practice workflow

ByBen H. Chew, MD, MSc

July 3rd 2026

Economic analysis: SURE reduces downstream stone costs

ByBrett Johnson, MD

July 1st 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery